[video+transcript]Why Alkermes' Depression Drug Stumbled, and How Illumina Plans to Profit From M&A

Millions of Americans suffer from depression, and there's a big unmet need for new depression drugs because about one-third of patients don't respond adequately to existing treatment options. To fill that need, Alkermes (NASDAQ:ALKS) developed ALKS-5461, a once-daily pill that combines an opioid with a compound that can prevent addiction.